Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas

2 years ago

by David Miller

966 Views

Written by David Miller

Priority Review granted to NDA for relapsed or refractory marginal zone lymphoma and mantle cell lymphoma Standard Review for NDA for relapsed or refractory follicular lymphoma WILMINGTON, Del.–(BUSINESS WIRE) November 1, 2021 — Incyte…Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

[mwai_chat window="true" fullscreen="true"]

You may also like

About the author

David Miller

Don`t Leave Yet!